Skip to main content
Premium Trial:

Request an Annual Quote

Strong Demand for Triple-TOF 5600 Drives AB Sciex's Q1 Revenue Growth

Premium

Danaher reported this week that core revenues at AB Sciex grew at high single-digit rates in the first quarter, driven by strong sales of its Triple-TOF 5600 mass spectrometer.

The "Triple-TOF 5600 led the way," Danaher CEO Larry Culp said during a conference call following the release of the earnings results, noting also that AB Sciex saw "robust demand" from the academic, proteomics, and applied markets.

He added that the company is "still in the early innings" with the instrument and that "customer acceptance and feedback on the product continues to be outstanding."

A full year into Danaher's acquisition of AB Sciex from Life Technologies, the company is "clearly seeing the benefits of new products, a much more focused go-to-market effort, and the implementation" of the Danaher Business System, a process to improve productivity, Culp said. Without elaborating, he hinted that there could be significant AB Sciex launches at the American Society for Mass Spectrometry conference in June.

In the company's Life Sciences and Diagnostics division, which houses AB Sciex, sales increased 22 percent to $626.6 million from $516.5 million during the first quarter of 2010.

As a whole, Danaher posted a profit of $429.4 million, or $.63 per share, up 43 percent from a year-ago profit of $300.2 million, or $.45 per share.

R&D spending for the first quarter totaled $217.6 million, up 20 percent from $180.8 million a year ago, while SG&A costs increased 12 percent to $969.7 million from $866.3 million a year ago.

The company said it had $1.59 billion in cash and cash equivalents as of April 1.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.